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Pathogens, especially viruses, evolve abilities to utilize cellular machineries to
facilitate their survival and propagation. Post-translational modifications (PTMs),
especially phosphorylation and SUMOylation, that reversibly modulate the function
and interactions of target proteins are among the most important features in cell
signaling pathways. PTM-dependent events also serve as one of the favorite targets
for viruses. Among the seven unambiguous human oncogenic viruses, hepatitis B
virus (HBV), hepatitis C virus (HCV), Epstein-Barr virus (EBV), Kaposi’s sarcoma-
associated herpesvirus (KSHV), human papillomavirus (HPV), Human T lymphotrophic
virus-1 (HTLV-1), and Merkel cell polyomavirus (MCPyV), two are herpesviruses.
The life cycle of herpesviruses consists of latent and lytic phases and the rapid
switch between these states includes global remodeling of the viral genome from
heterochromatin-to-euchromatin. The balance between lytic replication and latency is
essential for herpesvirus to maintain a persistent infection through a combination of
viral propagation and evasion of the host immune response, which consequently may
contribute to tumorigenesis. It is no surprise that the swift reversibility of PTMs, especially
SUMOylation, a modification that epigenetically regulates chromatin structure, is a major
hijack target of the host for oncogenic herpesviruses. In this brief review, we summarize
the varied ways in which herpesviruses engage the host immune components through
PTMs, focusing on phosphorylation and SUMOylation.
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POST-TRANSLATIONAL MODIFICATIONS (PTMS)
Post-translational modifications are reversible events that hold the key for the determination of
protein function and increase the functional diversity of proteins. Phosphorylation, one of the
most well-studied PTMs, regulates signal transduction through recruitment of different functional
partners. Tyrosine phosphorylation recruits Src homology 2 (SH2) or phosphotyrosine binding
(PTB) domain-containing proteins to propagate signaling events. Phospho-serine/threonine
can be recognized by protein modules including 14-3-3 proteins, WW domains, WD40
repeats and the BRCT motif. Small ubiquitin-like modifier (SUMO) is another important
PTM that was initially identified as an antagonist of ubiquitin (Ub). Ub is a small peptide
that was the first identified protein in Ub-like (UBL) proteins family and labels protein
through a conjugation system comprising E1 activation, E2 conjugation, and E3 ligation
enzymes. Proteins carrying Lys-48 poly-Ub chains are targeted to the proteasome and degraded
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(Komander and Rape, 2012). Proteins carrying Lys-63 poly-
Ub chains function as a scaffold to recruit proteins containing
Ub-binding domains (UBDs; Chen and Sun, 2009). Similarly,
SUMO-interacting motifs (SIMs) mediate the recognition of
SUMOylation and enables SUMO modifications to serve as a
platform to recruit additional proteins. Functioning as a scaffold
for DNA-binding proteins, SUMOylation mediates epigenetic
regulation of chromatin remodeling and transcription regulation.
Thus, SUMO has been one of the most intensively studied PTMs
in the context of chromatin-associated processes.
Many of the important immunomodulatory proteins and
chromatin remodeling molecules are functionally dependent
on and regulated by PTMs, primarily phosphorylation and
SUMOylation, respectively. Many cellular antiviral defense
systems recognize DNA viruses and limit their replication
and spread. It is not surprising that oncogenic herpesvirus,
including Epstein-Barr virus (EBV) and Kaposi’s sarcoma-
associated herpesvirus (KSHV), encode proteins that control
cellular PTM pathways to help their life cycle and evade host
immune responses [reviewed in (Wimmer et al., 2012; Everett
et al., 2013)]. The objective of this review is to focus on the current
knowledge on oncogenic γ-herpesvirus and phospho- and SUMO
modifications in immune regulation.
PTM AND IMMUNE FUNCTION
Oncogenic herpesviruses include EBV and KSHV. EBV mainly
infects B cells and causes lymphomas. KSHV infection is
associated with Kaposi’s sarcoma (KS), primary effusion
lymphomas (PEL), and multicentric Castlemen’s disease (Wen
and Damania, 2010). Herpesvirus enters into host cells via
two mechanisms: (i) direct membrane fusion: attachment and
fusion of the viral envelope with the cell plasma membrane
or (ii) endosome-dependent entry: receptor mediated binding
and internalization through interactions between viral envelope
glycoproteins with host cell surface molecules. Following capsid
disassembly, the viral DNA is released (Chandran, 2010). In
response to viral infection, the host innate immune system is
activated to control the virus. Innate immunity is the first-line
defense system of the host directed against virus through
recognition of pathogen-associated molecular patterns (PAMPs)
by pattern recognition receptors (PRRs). Exogenous viral DNA
in endosomes is recognized by Toll-like receptors 9 (TLR9).
Free exogenous viral DNA in the cytosol is recognized by either
Z-DNA binding protein 1 (ZBP1), absent in melanoma 2 (AIM2),
or cGAMP synthase (cGAS). Increasing evidence has shown
that promyelocytic leukemia protein-nuclear body (PML-NB)
may also mediate intrinsic immunity against viral DNA in the
nucleus.
Endosomal Toll-Like Receptors
Mediated Immune Response
In response to DNA viruses, endosome-bound TLR9 induces
a MyD88-dependent signaling with MyD88 forming complexes
with IRAK-1, IRAK-4 and interferon regulatory factor-7 (IRF-7),
which mediate the activation of type I interferon (IFN) pathway.
Similar to other transcription factors (TFs), IRF-7 undergoes
different PTMs, including phosphorylation, ubiquitylation, and
SUMOylation. There are several examples of herpesvirus proteins
targeting host IRFs. Open reading frame 45 (Orf45) of KSHV
competitively inhibits IRF-7 phosphorylation, which is essential
for IRF-7 transactivation activity (Zhu et al., 2002; Liang et al.,
2012). KSHV replication and transcription activator (K-Rta)
possesses Ub E3 ligase activity that mediates ubiquitylation and
subsequently proteasomal degradation of IRF-7 (Zhu et al., 2002).
miR-K12-11 encoded by KSHV inhibits IRF-3 phosphorylation,
which is responsible for IRF-3 activation, through targeting IKKε
(Liang et al., 2011). For EBV, latent membrane protein 1 (LMP1)
induces IRF-7 SUMOylation, that inhibits its transactivation
activity (Bentz et al., 2012) (Figure 1-I).
DNA and RNA-Induced Immune Reaction
Cytosolic exogenous double-stranded DNA (dsDNA) is
recognized by and triggers both Z-DNA binding protein 1/DNA-
dependent activator of IFN-regulatory factors (ZBP1/DAI) and
cGAMP synthase (cGAS) signaling that ultimately activates
IRF-3-dependent type I IFN response. ZBP1, the first cytosolic
dsDNA sensor, recruits TANK-binding kinase 1 (TBK1) and
IFN regulatory factor-3 (IRF-3), with the consequent induction
of type I IFN genes (Takaoka et al., 2007). cGAS, a member
of the nucleotidyltransferase family, binds to foreign dsDNA
in the cytoplasm and catalyzes cyclic GMP-AMP (cGAMP)
synthesis. cGAMP directly interacts with STING and induces
the STING-TBK1 signaling cascade that subsequently activates
IRF-3 and IFN-β production (Sun et al., 2013). In the ZBP1 and
cGAS pathway, EBV BGLF4 kinase phosphorylates IRF-3 and
inhibits the active IRF3 recruitment to ISREs and thus suppresses
the type I IFN response (Wang et al., 2009) (Figure 1-II). Other
inhibitory mechanisms employed by EBV which affect innate
immunity via phosphorylation includes latent membrane protein
1 (LMP-1) interaction with non-receptor tyrosine kinase 2
(Tyk2); an interaction that inhibits Tyk2 phosphorylation and
consequently prevents activation of IFN-α signaling (Geiger and
Martin, 2006). Cytosolic exogenous DNA also triggers AIM2
signaling that activates inflammasome-dependent pyroptosis. For
AIM2 signaling, though emerging reports show that recognition
of herpesvirus genomes by AIM-like receptor γ-interferon-
inducible protein 16 (IFI16) can induce acetylation of IFI16 and
IFI16-mediated inflammasome assembly (Ansari et al., 2015;
Dutta et al., 2015) (Figure 1-III), there is currently no evidence to
indicate that IFI16 acetylation is targeted by herpesviral proteins.
In addition to viral DNA, DNA virus encoded RNA can also
be recognized by RNA sensors such as RIG-I, which mediates
the type I IFN pathway against viral infection. RIG-I-mediated
signaling is controlled by ubiquitylation of RIG-I. Orf64
encoded by KSHV is a tegument protein with deubiquitinase
(DUB) activity. Orf64 suppresses RIG-I-mediated IFN signaling
by reducing the ubiquitylation of RIG-I (Inn et al., 2011)
(Figure 1-IV). This regulation is also observed in non-oncogenic
herpesvirus. For example, Orf63 encoded by α-herpesvirus
varicella zoster virus (VZV), the causative agent of chickenpox,
inhibits type I IFN signaling through proteasome-dependent
IRF-9 degradation (Verweij et al., 2015). All these existing
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FIGURE 1 | A schematic illustrating herpesvirus DNA and RNA-induced innate immune response and the links between viral protein and host innate
immune regulators. (I) TLR9-mediated recognition of cytosolic viral double-stranded DNA (dsDNA) in the endosome. (II) ZBP-1 binds viral DNA in cytoplasm.
(III) Activation of AIM2 inflammasome by viral DNA through binding of viral DNA to AIM-like receptor IFI16. (IV) RIG-I recognizes cytoplasmic viral RNA transcribed
from herpesvirus DNA. (V) Modulation of PML-NB by herpesvirus-encoded proteins.
findings suggest that targeting PTMs of various host pathogen
recognition receptors (PRR) or their down-stream effectors is
a common and efficient mechanism by which herpesviruses
suppress host innate immunity and facilitate intracellular host
survival.
Promyelocytic Leukemia-Nuclear Body
(PML-NB)
Accumulating evidence indicates that PML-NB, also known
as nuclear domain 10 (ND10) or PML oncogenic domains
(PODs), target herpesviruses by inhibiting viral transcription
and replication. PML-NB is a highly SUMO-modified nuclear
compartment that is permanently composed of PML, hDaxx,
and Sp100. Other factors can only be identified at PML-NB
under certain unique conditions. Soon after viral DNA enters
the nucleus, PML-NB rapidly associate with viral genomes in
a SUMO-dependent manner. It is thus not surprising that
herpesviruses have evolved mechanisms to target the SUMO
machinery as a means to counteract the PML-NB-mediated
antiviral response. Here, we focus on reviewing permanent
PML-NB components but also include few important PML-
NB variable proteins, such as ATRX that are targeted by
oncogenic herpesviruses. Modification of PML by SUMO is a
prerequisite for proper PML-NB formation. EBV BZLF1, also
known as Zta, is SUMO modified and competitively reduces
the SUMOylation of PML and consequently induces PML-NB
disruption (Adamson and Kenney, 2001) (Figure 1-V). EBV
EBNA1, one of the nuclear proteins of EBV that is expressed
during both latent and lytic phases, interacts with protein kinase
CK2 and consequently increases PML phosphorylation, and
subsequent polyubiquitylation and degradation (Sivachandran
et al., 2010) (Figure 1-V). KSHV immediate-early protein K-Rta
has recently been identified as a SUMO-Targeting Ubiquitin
Ligase (STUbL) that degraded SUMOylated PML and dispersed
PML-NBs during the viral lytic cycle (Izumiya et al., 2013)
(Figure 1-V). Emerging evidence suggests that, in addition to
silencing viral gene transcription, PML functions as a co-activator
of the type I IFN pathway (Scherer and Stamminger, 2016).
SUMO modification of PML may negatively regulate PML’s
ability to activate IFN signaling (Maarifi et al., 2015), however
the study of viral antagonism of the IFN-stimulating function
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of PML is still in its infancy. It has been documented in human
cytomegalovirus (HCMV), a β-herpesvirus, IE1 protein encoded
by HCMV counteracts the type I IFN response by sequestration of
interferon-stimulated gene factor 3 (ISGF3; Kim and Ahn, 2015;
Scherer et al., 2015).
HUMAN ONCOGENIC HERPESVIRAL
PROTEINS AND PTMS
In addition to regulating PML by SUMOylation, many
herpesviral proteins are themselves SUMO modified, as
mentioned earlier for EBV BZLF1. Both of the EBV immediate-
early proteins BRLF1/Rta (Chang et al., 2004) and BZLF1/Zta
(Hagemeier et al., 2010; Murata et al., 2010) can be SUMO
modified and SUMOylation is involved in the regulation of
their transactivation activity. EBV latent protein EBNA3C can
also be SUMO modified and this SUMOylation is essential for
EBNA3C coactivation activity with EBNA2 (Rosendorff et al.,
2004). Differing slightly from EBV, among the two immediate-
early proteins of KSHV, only K-bZIP, but not K-Rta, is efficiently
modified by SUMO (Izumiya et al., 2005). Interestingly, KSHV
K-Rta itself is a STUbL that mediated SUMO-dependent
degradation of SUMOylated viral and cellular proteins (Izumiya
et al., 2013). On the other hand, EBV BRLF1/Rta interacts with
the cellular STUbL, RNF4, and is regulated by RNF4 (Yang
et al., 2013). KSHV K-bZIP is not only SUMO modified, but
also been recently identified as a viral SUMO E3 ligase that can
SUMO modify many cellular proteins, including p53, IRF-1, and
IRF-2 (Chang et al., 2010, 2013). SUMOylation and SUMO E3
ligase activity of K-bZIP are both involved in its transrepression
activity (Izumiya et al., 2005; Yang et al., 2015). In addition to
targeting IRFs by SUMOylation, KSHV encodes many viral IRFs
(vIRF1–vIRF4) and vIRF3 was shown to be SUMO modified.
SUMOylation of vIRF3 is required for its ability to disrupt PML-
NB (Marcos-Villar et al., 2011). vIRF3 was also shown to interact
with and inhibit the SUMO modification of tumor suppressors
of pRb, p107, and p130 (Marcos-Villar et al., 2014). In addition,
KSHV latent protein LANA is also SUMO modified and contains
two SUMO interacting motifs (SIMs) within its N-terminus.
SIMs of LANA are essential for LANA-mediated recruitment
of SUMO-modified chromatin remodeling proteins including
KAP-1 (Cai et al., 2013).
Chromatin remodeling protein KAP-1 can also be regulated
by KSHV viral protein kinase (vPK). Phosphorylation of KAP-1
by vPK reduces KAP-1 SUMOylation and subsequently decreases
the binding ability of KAP-1 on chromatin (Chang et al., 2009).
Moreover, vPK also interacts with and phosphorylates KSHV
K-bZIP. Phosphorylation of K-bZIP reduced the SUMOylation
level and transrepression activity of K-bZIP (Izumiya et al., 2007).
EBV BGL4 kinase mediated a serial phosphorylation, through
TIP60 and ATM, to histone protein γ-H2AX and the chromatin
remodeling protein KAP-1. This creates an open chromatin
structure of viral episomes which facilitates viral lytic replication
(Li et al., 2012). EBV BGL4 also mediates the phosphorylation of
EBV BZLF1/Zta and consequently reduces the SUMOylation of
BZLF1/Zta (Hagemeier et al., 2010).
CONCLUSION AND FUTURE
PROSPECTS
Current knowledge of the mechanisms involved in viral infection
and tumor progression is still largely unknown. Emerging
evidence shows the importance of immune response in cancer.
Here, we summarize how the host cells use PTMs, especially
phosphorylation and SUMOylation, to regulate many important
immunomodulatory proteins. To survive in the host, viruses
express different proteins that target PTMs and consequently
repress host immune defenses. The potential mechanisms used by
oncogenic herpesvirus, including EBV and KSHV, are depicted.
Studying the interplay between virus and host immune system
will provide novel insight for development of future therapeutic
intervention in cancer.
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